Medical News

RSS

'Reaching the moon' in global public health

Citing President John F. Kennedy's "moon speech" -- in which Kennedy said, "We choose…because that goal will serve to organize and measure the best of our energies and skills, because that challenge is one that we are willing to accept, one we are unwilling to postpone, and one which we intend to win" --

24 Sep 2012

Study to examine SYMPLICITY renal denervation system for treatment-resistant hypertension

The University of Michigan Cardiovascular Center will participate in a national clinical trial to treat the most challenging form of high blood pressure.

24 Sep 2012

Advanced optics system noninvasively maps out network of tiny blood vessels beneath the skin

The trained eye of a dermatologist can identify many types of skin lesions, but human sight only goes so far. Now an international team of researchers has developed an advanced optics system to noninvasively map out the network of tiny blood vessels beneath the outer layer of patients' skin, potentially revealing telltale signs of disease.

24 Sep 2012

And about Paul Ryan...

Some conservatives want to hear more from the GOP vice presidential pick regarding his proposals for Medicare and Medicaid, and less of the campaign's more cautious talking points.

24 Sep 2012

Biologists unravel why some people infected with HIV have more virus

Biologists at UC San Diego have unraveled the anti-viral mechanism of a human gene that may explain why some people infected with HIV have much higher amounts of virus in their bloodstreams than others.

24 Sep 2012

Astellas seeks FDA approval for tacrolimus NDA for prophylaxis of organ rejection

Astellas Pharma US, Inc., a U.S. subsidiary of Tokyo-based Astellas Pharma Inc., today announced it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration seeking approval for tacrolimus extended release capsules for the prophylaxis of organ rejection in adult kidney transplant recipients and adult male liver transplant recipients.

24 Sep 2012

More money, focus needed to reach maternal, child health MDGs

Though the global community has "made incredible inroads" on the Millennium Development Goals (MDGs), "the majority of developing countries are still expected to fall short of the MDG targets for reducing maternal and child mortality by 2015," Carole Presern, director of the Partnership for Maternal, Newborn & Child Health (PMNCH), writes in the Huffington Post's "Global Motherhood" blog.

24 Sep 2012

Ohr commences Phase II clinical trial of Squalamine for wet-AMD

Ohr Pharmaceutical today announced the initiation of a Phase II clinical trial to evaluate the efficacy and safety of Squalamine Eye Drops for the treatment of the wet form of age-related macular degeneration.

24 Sep 2012

Low levels of vitamin D associated with higher risk of heart attack and early death

New research from the University of Copenhagen and Copenhagen University Hospital shows that low levels of vitamin D are associated with a markedly higher risk of heart attack and early death. The study involved more than 10,000 Danes and has been published in the well-reputed American journal Arteriosclerosis, Thrombosis and Vascular Biology.

24 Sep 2012

RXi completes dosing in RXI-109 Phase 1 study for dermal scarring

RXi Pharmaceuticals Corporation, a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, today announced that dosing with their first drug in its first Phase 1 study, was completed last week.

24 Sep 2012

Frontline health workers essential for newborn survival

"An infant's first moments and the twenty-eight days that follow are the most precarious, and her risk of death is never higher," but "[s]imple and inexpensive techniques, ... such as drying her, clearing her airway, keeping her warm or using a simple ventilation device to stimulate her breathing, can help," and frontline health workers "deliver these lifesaving techniques."

24 Sep 2012

Marijuana and testicular cancer: an interview with Victoria Cortessis

This is a set of malignancies that arise in germ cells of the testicles, the specialized cells that produce sperm. Taken together, testicular cancers are the most common form of malignancy that occurs in young men (approximately 15 to 35 years of age).

24 Sep 2012

Anesthetics and proteins: understanding the interactions

Spanish scientists at the University of the Basque Region and the University of La Rioja have combined mass-resolved electronic spectroscopy and ab initio calculations to model the interactions of anesthetics with proteins.

24 Sep 2012

Sanofi chooses OnPoint clinical trial management system from BioClinica

BioClinica, Inc., a global provider of clinical trial management services, announced today that Sanofi, one of the world's largest pharmaceutical companies, has selected BioClinica's OnPoint as the company's standard CTMS (Clinical Trial Management System).

From Clario 24 Sep 2012

Ziehm Imaging offers OR tables from Stille for vascular surgery

Effective immediately, Ziehm Imaging, the market and innovation leader for mobile C-arms, is offering OR tables from the Swedish manufacturer Stille to complement its Ziehm Vision RFD Hybrid Edition.

24 Sep 2012

NanoViricides’ oral FluCide dramatically improves survival in animals with H3N2 influenza A

NanoViricides, Inc. reported today that its oral FluCide drug candidates demonstrated dramatically improved survival in animals administered a lethal dose of the H3N2 influenza A virus.

24 Sep 2012

BioLineRx receives U.S. patent allowance for BL-1020 to treat schizophrenia

BioLineRx, a biopharmaceutical development company, announced today that a Notice of Allowance has been received from the United States Patent and Trademark Office (USPTO) claiming the crystalline form of BL-1020, a first-in-class orally available treatment for schizophrenia.

24 Sep 2012

Cannabis Science commences CSTATI-1 preclinical studies in Squamous/BCCs, Kaposi's sarcoma

Cannabis Science, a pioneering U.S. Biotech Company developing pharmaceutical products for global public health challenges, is pleased to announce preclinical investigations being initiated in Europe for Squamous/Basal Cell carcinomas and Kaposi's sarcoma based on inhibition of carcinogenicity utilizing cannabinoids that have been demonstrated in recent studies to significantly affect tumor necrosis.

24 Sep 2012

Valeant purchases QLT’s Visudyne

Valeant Pharmaceuticals International, Inc. announced today that it has acquired Visudyne, used to treat abnormal growth of leaky blood vessels in the eye caused by wet age-related macular degeneration, from QLT Inc.

24 Sep 2012

FDA clears Teleflex’s ARROW FlexBlock continuous peripheral nerve block catheter

Teleflex Incorporated today announced the ARROW FlexBlock continuous peripheral nerve block catheter has received 510(k) clearance from the U.S. Food and Drug Administration (FDA).

24 Sep 2012